| Donor clonal hematopoiesis and recipient outcomes after transplantation CJ Gibson, HT Kim, L Zhao, HM Murdock, B Hambley, A Ogata, ... Journal of Clinical Oncology 40 (2), 189-201, 2022 | 124 | 2022 |
| Hotspot SF3B1 mutations induce metabolic reprogramming and vulnerability to serine deprivation WB Dalton, E Helmenstine, N Walsh, LP Gondek, DS Kelkar, A Read, ... The Journal of clinical investigation 129 (11), 4708-4723, 2019 | 60 | 2019 |
| Hedgehog/GLI1 activation leads to leukemic transformation of myelodysplastic syndrome in vivo and GLI1 inhibition results in antitumor activity BW Lau, K Huh, R Madero-Marroquin, F De Marchi, Y Lim, Q Wang, ... Oncogene 38 (5), 687-698, 2019 | 23 | 2019 |
| Risk classification at diagnosis predicts post-HCT outcomes in intermediate-, adverse-risk, and KMT2A-rearranged AML K Menghrajani, A Gomez-Arteaga, R Madero-Marroquin, MJ Zhang, ... Blood advances 6 (3), 828-847, 2022 | 13 | 2022 |
| Durable responses in acute lymphoblastic leukaemia with the use of FLT3 and IDH inhibitors R Madero‐Marroquin, AS DuVall, C Saygin, P Wang, S Gurbuxani, ... British Journal of Haematology 204 (4), 1238-1242, 2024 | 6 | 2024 |
| Impact of fluoroquinolone prophylaxis on neutropenic fever, infections, and antimicrobial resistance in newly diagnosed AML patients J Caro, R Madero-Marroquin, N Zubizarreta, E Moshier, D Tremblay, ... Clinical Lymphoma Myeloma and Leukemia 22 (12), 903-911, 2022 | 6 | 2022 |
| Treatment approach and outcomes of patients with accelerated/blast-phase myeloproliferative neoplasms in the current era AA Patel, JJ Yoon, H Johnston, MB Davidson, RM Shallis, EC Chen, ... Blood advances 8 (13), 3468-3477, 2024 | 5 | 2024 |
| Clinical considerations at the intersection of hematopoietic cell transplantation and hereditary hematopoietic malignancy TE O’Connor, R Shaw, R Madero-Marroquin, GW Roloff Frontiers in Oncology 13, 1180439, 2023 | 2 | 2023 |
| Aberrant Hedgehog Signaling in Myelodysplastic Syndrome Accelerates Leukemic Transformation Via Smoothened-Dependent and Smoothened-Independent Gli1 Activation BW Lau, K Huh, R Madero-Marroquin, F De Marchi, Y Lim, F Lobo, ... Blood 130, 1676, 2017 | 2 | 2017 |
| Hedgehog/GLI1 Activation Leads to Leukemic Transformation of Myelodysplastic Syndrome BW Lau, K Huh, R Madero-Marroquin, F De Marchi, Y Lim, Q Wang Vivo, 0 | 2 | |
| CD58 expression does not impact response to inotuzumab ozogamicin in patients with B‐cell acute lymphoblastic leukemia R Madero‐Marroquin, RW Hunter, C Saygin, H Johnston, AS DuVall, ... eJHaem, 2024 | | 2024 |
| Interim Results of a Phase II Study Investigating Dasatinib and Inotuzumab Ozogamicin-Based Induction for Newly-Diagnosed Philadelphia-Chromosome Positive Acute Lymphoblastic … AA Patel, AS Duvall, C Saygin, H Weiner, E Dworkin, A Noorani, ... Blood 144, 1432, 2024 | | 2024 |
| Next-Generation Sequencing-Based T-Cell Receptor (TR) Measurable Residual Disease Monitoring Does Not Predict Relapse in T-Lineage Acute Lymphoblastic Leukemia R Madero-Marroquin, A Askari, YV Moreno, CE Anderson, T Badar, ... Blood 144, 5937, 2024 | | 2024 |
| Treatment of Anemia in Lower-Risk Myelodysplastic Syndrome MR Battaglia, J Cannova, R Madero-Marroquin, AA Patel Current Treatment Options in Oncology, 1-17, 2024 | | 2024 |
| Treatment outcomes of venetoclax-combination regimens for relapsed/refractory myeloid malignancies after anti-CD47-directed therapy R Madero-Marroquin, E Dworkin, H Weiner, C Saygin, MT Nawas, ... Leukemia & Lymphoma 65 (6), 864-867, 2024 | | 2024 |
| Durable Responses in Acute Lymphoblastic Leukemia Using Targeted Therapies Approved for Acute Myeloid Leukemia R Madero-Marroquin, P Wang, S Gurbuxani, A DuVall, A Patel International Journal of Cancer Care and Delivery 3 (Supplement 2), 2023 | | 2023 |
| Analysis of CD58 As a Predictive Marker of Morphologic Response to Inotuzumab Ozogamicin in Patients with B-Cell Acute Lymphoblastic Leukemia R Madero-Marroquin, R Hunter, C Saygin, H Johnston, HR Youshanlouei, ... Blood 142, 6071, 2023 | | 2023 |
| Risk classification at diagnosis predicts post-HCT outcomes in intermediate-, adverse-risk, and KMT2A-rearranged AML (vol 6, pg 828, 2022) K Menghrajani, A Gomez-Arteaga, R Madero-Marroquin BLOOD ADVANCES 7 (3), 395-395, 2023 | | 2023 |
| classification at diagnosis predicts post-HCT outcomes in intermediate-, adverse-risk, and KMT2A-rearranged AML. Blood Adv. 2022; 6 (3): 828-847. K Menghrajani, A Gomez-Arteaga, R Madero-Marroquin | | 2023 |
| Whole-exome sequencing identifies functional classes of gene mutations associated with bone marrow failure in pediatric Fanconi Anemia patients S Wang, NH Zbib, A Skaist, J Gui, R Madero-Marroquin, F De Marchi, ... European journal of haematology 107 (2), 293, 2021 | | 2021 |
